Obio Technology (Shanghai) Corp., Ltd. (688238)
Market Closed
11 Aug, 06:57
SSE SSE Primary ¥
7. 12
-0.05
-0.6974%
¥
3.78B Market Cap
- P/E Ratio
- Div Yield
28.21M Volume
- Eps
¥ 7.17
Previous Close Want to track 688238 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
688238 closed today lower at ¥7.12, a decrease of -0.6974% from yesterday's close, completing a monthly increase of 31.3653% or ¥1.7. Over the past 12 months, 688238 stock gained 6.5868%.
688238 is not paying dividends to its shareholders.
The last earnings report, released on Oct 23, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Obio Technology (Shanghai) Corp., Ltd. has completed 1 stock splits, with the recent split occurring on May 30, 2023.
The company's stock is traded on one exchange.
688238 Chart
People also search for
Obio Technology (Shanghai) Corp., Ltd. (688238) FAQ
What is the stock price today?
The current price is ¥7.12.
On which exchange is it traded?
Obio Technology (Shanghai) Corp., Ltd. is listed on SSE.
What is its stock symbol?
The ticker symbol is 688238.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 3.78B.
Has Obio Technology (Shanghai) Corp., Ltd. ever had a stock split?
Obio Technology (Shanghai) Corp., Ltd. had 1 splits and the recent split was on May 30, 2023.
Obio Technology (Shanghai) Corp., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Oudong Pan CEO | SSE Exchange | - ISIN |
| CN Country | 731 Employees | - Last Dividend | 30 May 2023 Last Split | - IPO Date |
Overview
Obio Technology (Shanghai) Corp., Ltd. stands as a pioneering biotechnology entity based in China, with its inception dating back to 2013. This company has positioned itself at the forefront of gene therapy vectors' development, catering to the expansive needs of gene function and therapy research within the Chinese market. With its headquarters nestled in the vibrant city of Shanghai, Obio Technology demonstrates a steadfast commitment to advancing the field of genetic drugs through cutting-edge research and development initiatives.
Products and Services
Obio Technology offers an array of products and services meticulously designed to support and propel the research and development in the realm of genetic drugs. These offerings are detailed as follows:
- Gene Function and Gene Therapy Research: This core service encompasses comprehensive research capabilities in understanding gene functions and their potential therapeutic applications. By leveraging their specialized knowledge and technological advancements, Obio Technology aids in uncovering the transformative potential of gene therapy for various diseases.
- Contract Research Organization (CRO) Services: The company provides tailored CRO services focusing on drug target identification and drug efficacy research. These services are pivotal for entities looking to streamline their drug discovery and development processes, ensuring the delivery of impactful and innovative therapeutic solutions.
- Contract Development and Manufacturing Organization (CDMO) Services: Obio Technology extends its expertise to cover the full spectrum of CDMO services, including process development and testing, IND-CMC pharmaceutical research, and clinical sample GMP production. These services emphasize the critical aspects of manufacturing and quality control in the lifecycle of genetic drug development, facilitating the transition from research to clinical applications.
Contact Information
Address: Building 19, Shanghai, China, 201321
Phone: 86 21 5858 5887
Website: https://www.obiosh.com
